Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations
November 21 2017 - 4:45PM
Business Wire
-- Presentations to be webcast on
www.exelixis.com --
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.
Morrissey, Ph.D., the company’s President and Chief Executive
Officer, will provide an overview of the company at the following
two investor conferences in the coming weeks:
- Piper Jaffray 29th Annual Healthcare
Conference: Exelixis’ presentation is scheduled for 11:00 AM EST /
8:00 AM PST on Tuesday, November 28, 2017 in New York, NY.
- Evercore ISI 2017 Biopharma
Catalyst/Deep Dive Conference: Exelixis’ presentation is scheduled
for 12:05 PM EST / 9:05 AM PST on Wednesday, November 29, 2017 in
Boston, MA.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the presentation to ensure
adequate time for any software download that may be required to
listen to the webcast. A replay will also be available at the same
location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before
entering into partnerships with leading biopharmaceutical companies
in our efforts to bring them to patients globally. We are steadfast
in our commitment to prudently reinvest in our business to maximize
the potential of our pipeline. We intend to supplement our existing
therapeutic assets with targeted business development activities
and internal drug discovery – all to deliver the next generation of
Exelixis medicines and help patients recover stronger and live
longer. Exelixis recently earned a spot on Deloitte’s Technology
Fast 500 list, a yearly award program honoring the 500
fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com or follow
@ExelixisInc on Twitter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171121006080/en/
Investors Contact:Exelixis, Inc.Susan Hubbard,
650-837-8194EVP, Public Affairs and Investor
Relationsshubbard@exelixis.comorMedia Contact:For Exelixis,
Inc.Hal Mackins, 415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024